JP2017513849A - Ａ群レンサ球菌ワクチン - Google Patents

Ａ群レンサ球菌ワクチン Download PDF

Info

Publication number
JP2017513849A
JP2017513849A JP2016562764A JP2016562764A JP2017513849A JP 2017513849 A JP2017513849 A JP 2017513849A JP 2016562764 A JP2016562764 A JP 2016562764A JP 2016562764 A JP2016562764 A JP 2016562764A JP 2017513849 A JP2017513849 A JP 2017513849A
Authority
JP
Japan
Prior art keywords
seq
fragment
peptide
amino acid
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016562764A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017513849A5 (enExample
Inventor
パンディ、マニシャ
バツロフ、マイケル
グッド、マイケル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Griffith University
Original Assignee
Griffith University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2014901382A external-priority patent/AU2014901382A0/en
Application filed by Griffith University filed Critical Griffith University
Publication of JP2017513849A publication Critical patent/JP2017513849A/ja
Publication of JP2017513849A5 publication Critical patent/JP2017513849A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2016562764A 2014-04-15 2015-04-15 Ａ群レンサ球菌ワクチン Pending JP2017513849A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
AU2014901382 2014-04-15
AU2014901382A AU2014901382A0 (en) 2014-04-15 Group a streptococcal vaccine
AU2014903042 2014-08-06
AU2014903042A AU2014903042A0 (en) 2014-08-06 Group a streptococcal vaccine
AU2014904453 2014-11-05
AU2014904453A AU2014904453A0 (en) 2014-11-05 Group a streptococcal vaccine
PCT/AU2015/050174 WO2015157820A1 (en) 2014-04-15 2015-04-15 Group a streptococcus vaccine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020201171A Division JP7072921B2 (ja) 2014-04-15 2020-12-03 Ａ群レンサ球菌ワクチン

Publications (2)

Publication Number Publication Date
JP2017513849A true JP2017513849A (ja) 2017-06-01
JP2017513849A5 JP2017513849A5 (enExample) 2018-04-26

Family

ID=54323282

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016562764A Pending JP2017513849A (ja) 2014-04-15 2015-04-15 Ａ群レンサ球菌ワクチン
JP2020201171A Active JP7072921B2 (ja) 2014-04-15 2020-12-03 Ａ群レンサ球菌ワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020201171A Active JP7072921B2 (ja) 2014-04-15 2020-12-03 Ａ群レンサ球菌ワクチン

Country Status (16)

Country Link
US (2) US10301362B2 (enExample)
EP (1) EP3131575B1 (enExample)
JP (2) JP2017513849A (enExample)
KR (2) KR102730367B1 (enExample)
CN (1) CN106794236B (enExample)
AU (1) AU2015246654B2 (enExample)
BR (1) BR112016023915B1 (enExample)
CA (1) CA2945052C (enExample)
DK (1) DK3131575T3 (enExample)
IL (1) IL248266B (enExample)
MX (1) MX392514B (enExample)
MY (1) MY191217A (enExample)
NZ (1) NZ725212A (enExample)
SG (1) SG11201608380PA (enExample)
WO (1) WO2015157820A1 (enExample)
ZA (1) ZA201607355B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021532151A (ja) * 2018-07-27 2021-11-25 ヒノバ ファーマシューティカルズ インコーポレイテッド Ｂｒｄ４阻害剤及びその製造方法と使用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102730367B1 (ko) 2014-04-15 2024-11-15 그리피스 유니버시티 그룹 a 스트렙토코쿠스 백신
CN106606775A (zh) * 2015-10-27 2017-05-03 格里菲斯大学 脂质体a群链球菌疫苗
TWI598360B (zh) * 2016-12-19 2017-09-11 義守大學 Ｆｓｂｍ重組蛋白及其用途
CN111344007A (zh) * 2017-08-23 2020-06-26 格里菲斯大学 抗a组链球菌的免疫原性肽
KR102437436B1 (ko) * 2019-04-26 2022-08-30 주식회사 엠디헬스케어 스트렙토코커스 파이오제네스 세균 유래 단백질 및 이의 용도
NL2023863B1 (en) 2019-09-20 2021-05-25 Univ Griffith Protein particles and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996011944A1 (en) * 1994-10-14 1996-04-25 The Council Of The Queensland Institute Of Medical Research Synthetic peptides and vaccines comprising same
JP2008540417A (ja) * 2005-05-05 2008-11-20 メルク エンド カムパニー インコーポレーテッド ペプチドコンジュゲート組成物およびアルツハイマー病の予防および治療のための方法
US20090010929A1 (en) * 2006-12-04 2009-01-08 Good Michael F Therapeutic Antibodies, Antibody Fragments and Antibody Conjugates
JP2010538634A (ja) * 2007-09-12 2010-12-16 ノバルティス アーゲー Ｇａｓ５７変異体抗原およびｇａｓ５７抗体
JP2012502969A (ja) * 2008-09-17 2012-02-02 ノバルティス アーゲー 組み合わせｇａｓワクチンおよび治療法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047238A (en) 1983-06-15 1991-09-10 American Home Products Corporation Adjuvants for vaccines
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5811105A (en) 1987-12-23 1998-09-22 Glaxo Wellcome, Inc. Vaccines containing bacteria attenuated by mutations in two genes of the aromatic amino acid biosynthetic pathway
US5785973A (en) 1988-02-01 1998-07-28 Praxis Biologics, Inc. Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
GB8912330D0 (en) 1989-05-30 1989-07-12 Wellcome Found Live vaccines
GB9007194D0 (en) 1990-03-30 1990-05-30 Wellcome Found Live vaccines
AUPO007396A0 (en) 1996-05-24 1996-06-20 Csl Limited Ebv ctl epitopes
AUPO784197A0 (en) 1997-07-10 1997-08-07 Csl Limited Treatment of nasopharyngeal carcinoma
EP1807446A2 (en) * 2004-10-08 2007-07-18 Novartis Vaccines and Diagnostics, Inc. Immunogenic and therapeutic compositions for streptococcus pyogenes
JP5102772B2 (ja) 2005-11-29 2012-12-19 ザ・ユニバーシティ・オブ・シドニー デミボディ：二量体化活性化治療剤
EP2059531A1 (en) 2006-07-07 2009-05-20 Intercell AG Small streptococcus pyogenes antigens and their use
US8482298B2 (en) 2006-12-18 2013-07-09 Schrader Electronics Ltd. Liquid level and composition sensing systems and methods using EMF wave propagation
US20090162369A1 (en) * 2007-12-12 2009-06-25 Katin Helena Threse Nordstrom Synthetic chimeric peptides
KR102730367B1 (ko) 2014-04-15 2024-11-15 그리피스 유니버시티 그룹 a 스트렙토코쿠스 백신
CN111344007A (zh) * 2017-08-23 2020-06-26 格里菲斯大学 抗a组链球菌的免疫原性肽

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996011944A1 (en) * 1994-10-14 1996-04-25 The Council Of The Queensland Institute Of Medical Research Synthetic peptides and vaccines comprising same
JP2008540417A (ja) * 2005-05-05 2008-11-20 メルク エンド カムパニー インコーポレーテッド ペプチドコンジュゲート組成物およびアルツハイマー病の予防および治療のための方法
US20090010929A1 (en) * 2006-12-04 2009-01-08 Good Michael F Therapeutic Antibodies, Antibody Fragments and Antibody Conjugates
JP2010538634A (ja) * 2007-09-12 2010-12-16 ノバルティス アーゲー Ｇａｓ５７変異体抗原およびｇａｓ５７抗体
JP2012502969A (ja) * 2008-09-17 2012-02-02 ノバルティス アーゲー 組み合わせｇａｓワクチンおよび治療法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J. IMMUNOL., vol. Vol.190(6), JPN6018051513, 2013, pages 2692 - 2701, ISSN: 0003949077 *
感染症学雑誌, vol. 第８３巻 第５号, JPN6018051510, 2009, pages 485 - 489, ISSN: 0003949076 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021532151A (ja) * 2018-07-27 2021-11-25 ヒノバ ファーマシューティカルズ インコーポレイテッド Ｂｒｄ４阻害剤及びその製造方法と使用
JP7531479B2 (ja) 2018-07-27 2024-08-09 ヒノバ ファーマシューティカルズ インコーポレイテッド Ｂｒｄ４阻害剤及びその製造方法と使用

Also Published As

Publication number Publication date
MY191217A (en) 2022-06-09
CN106794236B (zh) 2021-09-03
KR20230039751A (ko) 2023-03-21
KR20160144455A (ko) 2016-12-16
IL248266A0 (en) 2016-11-30
JP7072921B2 (ja) 2022-05-23
CN106794236A (zh) 2017-05-31
AU2015246654B2 (en) 2019-08-08
EP3131575A4 (en) 2017-11-01
BR112016023915B1 (pt) 2024-03-12
DK3131575T3 (da) 2024-05-21
CA2945052C (en) 2023-05-02
KR102730367B1 (ko) 2024-11-15
MX2016013277A (es) 2017-01-18
WO2015157820A1 (en) 2015-10-22
US20190256562A1 (en) 2019-08-22
NZ725212A (en) 2023-04-28
CA2945052A1 (en) 2015-10-22
MX392514B (es) 2025-03-24
ZA201607355B (en) 2019-03-27
BR112016023915A2 (pt) 2017-10-17
AU2015246654A1 (en) 2016-11-03
EP3131575B1 (en) 2024-05-08
US10301362B2 (en) 2019-05-28
US10513544B2 (en) 2019-12-24
IL248266B (en) 2021-09-30
SG11201608380PA (en) 2016-11-29
KR102744193B1 (ko) 2024-12-19
US20170037087A1 (en) 2017-02-09
EP3131575A1 (en) 2017-02-22
JP2021042247A (ja) 2021-03-18

Similar Documents

Publication Publication Date Title
JP7072921B2 (ja) Ａ群レンサ球菌ワクチン
JP5746333B2 (ja) カンピロバクター感染を減少させるワクチン及び方法
KR102228324B1 (ko) 에이메리아에 대한 면역 반응을 증진시키거나, 에이메리아 감염을 제한하는 조성물 및 방법
JP2023025066A (ja) ワクチン構築物およびブドウ球菌感染症に対するその使用
US12383630B2 (en) Immunogenic peptide against group a Streptococcus
KR20210010882A (ko) 연쇄구균 독성 쇼크 증후군
RU2775621C2 (ru) Иммуногенный пептид против стрептококков группы а
KR102893870B1 (ko) 그룹 a 스트렙토코쿠스에 대한 면역원성 펩티드
HK1238144A1 (en) Group a streptococcus vaccine
HK1238144B (zh) A群链球菌疫苗
WO2023081861A9 (en) Enhanced expression via autotransporters
US20180243392A1 (en) Cs21 and lnga protein vaccines

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180314

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180314

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190108

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190408

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190610

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200408

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200804